drugset / Trial / NCT04011241

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood

NCT04011241

Phase 1 Completed 14 enrolled Boehringer Ingelheim
Non-randomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test,T) as compared to when given alone as oral single dose (Reference, R).

Timeline

Start
2019-07-24
Primary completion
2019-09-06
Completion
2019-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1323495 Unknown 10 mg Oral
Background Itraconazole Small molecule 200 mg Oral

Indications

No indication recorded.